Pharmaceuticals

Anthrax Vaccine Market Forecast 2026–2035: Data Trends and Industry Insights

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anthrax vaccine market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Anthrax Vaccine Market show for the 2026–2030 period?

The anthrax vaccine market has experienced consistent expansion in recent years. It is anticipated to increase from $11.77 billion in 2025 to $12.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.7%. In previous periods, this growth was primarily due to the widespread presence of anthrax in livestock, vaccination programs led by governments, ongoing research in immunology, existing limited vaccine production capacity, and greater awareness regarding occupational exposure.

The anthrax vaccine market is anticipated to exhibit steady expansion over the next few years, with its value forecast to reach $14.49 billion by 2030, propelled by a compound annual growth rate (CAGR) of 4.1%. This projected growth in the forecast period can be ascribed to factors such as the development of recombinant and next-generation vaccines, a rising demand for human and animal prophylaxis, advancements in vaccine delivery technologies, the expansion of biodefense programs, and collaborations between the pharmaceutical and defense sectors. Prominent trends for the forecast period include advanced vaccine formulations, expanded immunization programs, innovations in cold chain and storage, enhanced biodefense and pandemic preparedness, and government and military vaccination initiatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What Drivers Are Shaping The Development Of The Anthrax Vaccine Market?

The anthrax vaccine market is anticipated to experience growth driven by the increasing occurrence of infectious diseases. These illnesses are defined as conditions resulting from pathogenic microorganisms like bacteria, viruses, parasites, or fungi, capable of transmitting between individuals either directly or indirectly, and presenting symptoms that vary from mild to severe or even deadly, contingent on the specific pathogen and the host’s immune system. Factors contributing to the widespread presence of infectious diseases include global population demographic shifts, increased urbanization, alterations in environmental conditions and land utilization, and evolving human behaviors. While the anthrax vaccine is primarily used for protection against anthrax, ongoing research into its immunogenic characteristics and adaptability is exploring its potential for wider application in preventing various other infectious diseases. For example, data from February 2023 by the Council on Foreign Relations, a US-based nonprofit, indicated that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of established infectious diseases originated from animals (zoonotic). Moreover, globally, zoonotic diseases are responsible for 2.7 million human deaths and 2.5 billion disease incidents annually. Consequently, the increasing incidence of these diseases is a key factor propelling the expansion of the anthrax vaccine market.

What Segment Types Are Examined In The Anthrax Vaccine Market?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Trends Are Expected To Influence The Anthrax Vaccine Market In The Upcoming Years?

Leading companies within the anthrax vaccine market are concentrating on developing innovative products and securing FDA clearances for their vaccines to guarantee their safety, efficacy, and availability for those at risk of anthrax exposure. Obtaining FDA approval ensures the vaccine undergoes rigorous testing in clinical trials and is proven safe for public use, thereby helping to protect individuals from potential adverse effects. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), which was previously known as AV7909. This approval was predicated on data from a Phase 2 trial that assessed Cyfendus’s non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the earlier anthrax vaccine. Furthermore, the development of safer and more effective adjuvants is essential to address reactogenicity-related issues and enhance the general efficiency of anthrax vaccines.

Who Are The Core Companies Influencing Trends In The Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Regions Are Projected To Dominate The Anthrax Vaccine Market In The Coming Years?

North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anthrax Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2026, By The Business Research Company

Anthrax Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Anthrax Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Anthracycline Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795